Iteos Therapeutics Inc
ITOS10.095USD
+0.005+0.05%
交易中 （美東）報價延遲15分鐘
386.35M總市值
虧損本益比TTM
關於 Iteos Therapeutics Inc 公司
iTeos Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於爲癌症患者發現和開發新一代免疫腫瘤療法。其產品線包括三個臨牀階段項目，針對新穎、經過驗證的免疫腫瘤途徑。其主要抗體候選產品 belrestotug（也稱爲 EOS-448/GSK4428859A）是 TIGIT 的拮抗劑，TIGIT 是一種具有多種作用機制的免疫檢查點。其高級項目是 inupadenant，也稱爲 EOS-850，這是一種下一代腺苷 2A 受體 (A2AR) 拮抗劑，專門用於克服腫瘤微環境中發現的特定腺苷介導的免疫抑制。其啓動臨牀試驗的項目是 EOS-984，這是一種潛在的同類首創小分子，專注於腺苷途徑中的一種新機制，通過靶向平衡核苷轉運蛋白 1（ENT1），即參與 T 細胞代謝的淋巴細胞上腺苷的主要轉運蛋白。
公司簡介
公司代碼ITOS
公司名稱Iteos Therapeutics Inc
上市日期Jul 24, 2020
CEODr. Michel Marcel Detheux, Ph.D.
員工數量173
證券類型Ordinary Share
年結日Jul 24
公司地址321 Arsenal Street
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02472
電話18572044583
網址https://www.iteostherapeutics.com/
公司代碼ITOS
上市日期Jul 24, 2020
CEODr. Michel Marcel Detheux, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Matthew Gall
Mr. Matthew Gall
Chief Financial Officer
Chief Financial Officer
89.43K
+36.68%
Dr. Yvonne Mcgrath, Ph.D.
Dr. Yvonne Mcgrath, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.30K
+49.35%
Mr. David L. Hallal
Mr. David L. Hallal
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
200.00
--
Dr. David Feltquate, M.D., Ph.D.
Dr. David Feltquate, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
--
Dr. Tony W. Ho, M.D.
Dr. Tony W. Ho, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Call
Mr. Matthew (Matt) Call
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Jill Desimone
Ms. Jill Desimone
Independent Director
Independent Director
--
--
Mr. David K. Lee
Mr. David K. Lee
Independent Director
Independent Director
--
--
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Matthew Gall
Mr. Matthew Gall
Chief Financial Officer
Chief Financial Officer
89.43K
+36.68%
Dr. Yvonne Mcgrath, Ph.D.
Dr. Yvonne Mcgrath, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.30K
+49.35%
Mr. David L. Hallal
Mr. David L. Hallal
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
200.00
--
Dr. David Feltquate, M.D., Ph.D.
Dr. David Feltquate, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
--
Dr. Tony W. Ho, M.D.
Dr. Tony W. Ho, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月4日 週五
更新時間: 7月4日 週五
持股股東
股東類型
持股股東
持股股東
佔比
EcoR1 Capital, LLC
24.20%
Tang Capital Management, LLC
8.66%
BVF Partners L.P.
6.96%
BlackRock Institutional Trust Company, N.A.
6.61%
RA Capital Management, LP
4.83%
Other
48.73%
持股股東
持股股東
佔比
EcoR1 Capital, LLC
24.20%
Tang Capital Management, LLC
8.66%
BVF Partners L.P.
6.96%
BlackRock Institutional Trust Company, N.A.
6.61%
RA Capital Management, LP
4.83%
Other
48.73%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
44.00%
Hedge Fund
32.73%
Investment Advisor
18.71%
Venture Capital
4.83%
Research Firm
4.03%
Individual Investor
1.18%
Bank and Trust
0.24%
Pension Fund
0.04%
Family Office
0.03%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
356
46.25M
106.55%
-2.06M
2025Q1
370
38.09M
99.61%
-6.00M
2024Q4
371
35.32M
96.67%
-8.51M
2024Q3
369
38.37M
105.07%
-5.97M
2024Q2
373
37.75M
104.49%
-5.18M
2024Q1
379
35.71M
99.63%
-7.84M
2023Q4
383
36.12M
100.93%
-6.72M
2023Q3
372
36.95M
103.27%
-4.10M
2023Q2
371
36.77M
102.82%
-4.92M
2023Q1
370
37.66M
105.32%
-4.62M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
EcoR1 Capital, LLC
10.69M
27.93%
+10.69M
--
May 15, 2025
Tang Capital Management, LLC
3.83M
10%
--
--
Jun 11, 2025
BVF Partners L.P.
3.08M
8.03%
+750.00K
+32.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.92M
7.63%
+313.58K
+12.03%
Mar 31, 2025
RA Capital Management, LP
2.13M
5.58%
-1.51M
-41.50%
May 19, 2025
Ridgeback Capital Management, L.P.
1.44M
3.77%
+1.44M
--
May 28, 2025
683 Capital Management LLC
1.75M
4.57%
+831.88K
+90.61%
Mar 31, 2025
The Vanguard Group, Inc.
1.73M
4.51%
+92.43K
+5.66%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.22M
3.18%
+383.07K
+45.83%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.18M
3.09%
-28.83K
-2.38%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
ALPS Medical Breakthroughs ETF
0.26%
JPMorgan Fundamental Data Science Small Core ETF
0.22%
iShares Micro-Cap ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Avantis US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.9%
ALPS Medical Breakthroughs ETF
佔比0.26%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.22%
iShares Micro-Cap ETF
佔比0.07%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
Avantis US Small Cap Equity ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.04%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.03%
Fidelity Enhanced Small Cap ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
